Amyotrophic Lateral Sclerosis, ALS, or Frontotemporal Dementia FTD, (NCT04931862)
Sponsors:
Wave Life Sciences Ltd.
Sponsors:
Wave Life Sciences Ltd.
IND Enabling
Phase I
Phase II
Phase III
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Wave Life Sciences
Company Type: Therapeutics
Main focus: Antisense oligonucleotides, RNAi and RNA editing
Company stage: IPO ( WVE)
Diseases: Duchenne muscular dystrophy
Genome-editing tool: GalNAc-conjugated RNA-editing oligonucleotide
Funding stage: I
Location: Cambridge, MA, USA
Website: https://wavelifesciences.com/
Pipeline: https://wavelifesciences.com/pipeline/
Partners: GSK; Takeda
Wave Life Sciences is a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aims develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company’s proprietary discovery and drug development platform that enables the precise design, optimisation, and production of stereopure oligonucleotides.
Tags
Clinical Trials
IND Enabling
Phase I
Phase II
Phase III
Amyotrophic Lateral Sclerosis, ALS, and Frontotemporal Dementia, FTD, (NCT05683860)
Sponsors:
Wave Life Sciences Ltd.
Sponsors:
Wave Life Sciences Ltd.
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
IND Enabling
Phase I
Phase II
Phase III
